20/20 Biolabs Inc (AIDX)

Common Shares

Sell: $1.77|Buy: $1.92|Change: 0.05 (-2.66%)

Open

$1.80

Previous close

$1.88

Trade high

$1.91

Volume

57,167

Year high

$50.00

Year low

$1.51

Dividend yield

–

Market capitalisation

$18.94 mn

P/E ratio

–

ISIN

US90138K1016

This share can be held in a Dealing account

Share price

Performance 02/04/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
20/20 Biolabs Inc	- 2.66
More...

Company profile

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity thatconsists of inflammatory biomarkers.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.